| 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|
| 营业收入(元) | |||
| 口服溶液(元) | 2,231,786.62 | 4,202,037.58 | 1,277,675.15 |
| 口服液(元) | 557,342.46 | 3,272,413.25 | 1,972,316.79 |
| 片剂(元) | 10,586,030.95 | 14,698,426.00 | 8,090,132.84 |
| 软膏剂(元) | 7,495,300.94 | 17,654,437.40 | 7,289,591.37 |
| 原料原料药(元) | 14,854,501.45 | 22,812,234.10 | 16,007,519.20 |
| 制剂原料药(元) | 1,136,447.44 | 3,019,561.85 | 1,239,557.55 |
| 中间体原料药(元) | 10,420,069.01 | 35,028,720.20 | 10,506,550.61 |
| 营业成本(元) | |||
| 口服溶液(元) | 1,232,422.18 | 3,225,856.36 | 1,004,746.20 |
| 口服液(元) | 620,586.44 | 3,270,321.77 | 1,895,391.71 |
| 片剂(元) | 11,519,232.03 | 14,616,757.07 | 7,891,125.49 |
| 软膏剂(元) | 1,856,010.50 | 4,747,068.53 | 1,809,791.23 |
| 原料原料药(元) | 5,273,875.12 | 13,974,524.90 | 9,053,397.95 |
| 制剂原料药(元) | 858,800.98 | 2,191,300.16 | 916,633.92 |
| 中间体原料药(元) | 10,116,283.07 | 36,252,532.01 | 11,078,043.92 |
| 毛利(元) | |||
| 口服溶液(元) | 999,364.44 | 976,181.22 | 272,928.95 |
| 口服液(元) | -63,243.98 | 2,091.48 | 76,925.08 |
| 片剂(元) | -933,201.08 | 81,668.93 | 199,007.35 |
| 软膏剂(元) | 5,639,290.44 | 12,907,368.87 | 5,479,800.14 |
| 原料原料药(元) | 9,580,626.33 | 8,837,709.20 | 6,954,121.25 |
| 制剂原料药(元) | 277,646.46 | 828,261.69 | 322,923.63 |
| 中间体原料药(元) | 303,785.94 | -1,223,811.81 | -571,493.31 |
| 毛利率(%) | |||
| 口服溶液(%) | 44.78 | 23.23 | 21.36 |
| 口服液(%) | -11.35 | 0.06 | 3.90 |
| 片剂(%) | -8.82 | 0.56 | 2.46 |
| 软膏剂(%) | 75.24 | 73.11 | 75.17 |
| 原料原料药(%) | 64.50 | 38.74 | 43.44 |
| 制剂原料药(%) | 24.43 | 27.43 | 26.05 |
| 中间体原料药(%) | 2.92 | -3.49 | -5.44 |
| 收入构成(%) | |||
| 口服溶液(%) | 4.72 | 4.17 | 2.75 |
| 口服液(%) | 1.18 | 3.25 | 4.25 |
| 片剂(%) | 22.39 | 14.60 | 17.44 |
| 软膏剂(%) | 15.85 | 17.53 | 15.72 |
| 原料原料药(%) | 31.42 | 22.66 | 34.51 |
| 制剂原料药(%) | 2.40 | 3.00 | 2.67 |
| 中间体原料药(%) | 22.04 | 34.79 | 22.65 |
| 毛利构成(%) | |||
| 口服溶液(%) | 6.32 | 4.36 | 2.14 |
| 口服液(%) | -0.40 | 0.01 | 0.60 |
| 片剂(%) | -5.90 | 0.36 | 1.56 |
| 软膏剂(%) | 35.68 | 57.60 | 43.03 |
| 原料原料药(%) | 60.62 | 39.44 | 54.61 |
| 制剂原料药(%) | 1.76 | 3.70 | 2.54 |
| 中间体原料药(%) | 1.92 | -5.46 | -4.49 |